In the realm of diabetes research, the utilization of in vitro models has emerged as a pivotal tool in unraveling the intricate cellular and molecular mechanisms that underlie this widespread metabolic disorder. Ace Therapeutics is committed to establishing in vitro models of diabetes mellitus (DM), including pancreatic islet cell models and insulin resistance (IR) models, offering a specialized platform to explore DM pathophysiology.
DM is a group of metabolic diseases characterized by hyperglycemia. IR and insufficient insulin secretion are important pathophysiological basis and significant features of DM. Traditional DM research and hypoglycemic drug screening rely heavily on animal models, leading to lengthy, complex, and costly experiments. In recent years, cell-based models have gained traction as they offer a more efficient, cost-effective, and objective approach to studying hypoglycemic drugs and mechanisms. These models allow for controlled experimentation, making them valuable for drug screening, toxicity assessment, molecular pharmacology, and various other research areas.
Fig. 1. Stem-cell-based organ-on-a-chip models of diabetes. (Rogal J, et al., 2019)
At Ace Therapeutics, we focus on inducing cellular damage and IR through high insulin, high glucose, high free fatty acids, STZ, dexamethasone, AXN, etc. In addition, we use 3D culture and co-culture methods to simulate the real environment for in vitro cells.
By harnessing the power of advanced cellular technologies and multidisciplinary expertise, we aim to use appropriate inducers and cell types to establish different types of diabetes cell models according to our client's research needs.
By meticulously culturing and maintaining primary islet cells or engineered cell lines, our advanced modeling systems faithfully recapitulate the physiological functions and responses of key cell types within the pancreas. By combining these models with advanced analytical techniques such as high throughput screening and metabolic flux analysis, we assist clients in researching complex regulatory networks that control glucose homeostasis.
Through the manipulation of factors like fatty acid exposure and proinflammatory cytokine treatment, our researchers can replicate the conditions conducive to IR development in cell lines such as C2C12 myotubes and HepG2 cells. We provide various induction methods based on our client's research needs and use these cell models to elucidate the signaling pathways involved in IR and identify new therapeutic targets.
Innovative measurement and cell culture methods are key to studying disease models and developing therapies. We help clients analyze various metabolic processes of DM models, which is crucial for studying diabetes and finding new therapeutic targets and drugs.
Please contact us for more information about how our in vitro models can be customized to meet your exact needs. Through the utilization of advanced pancreatic islet cell models and IR models, researchers are expected to unravel the mysteries of diabetes pathophysiology and accelerate the development of innovative drugs.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
